Hey Buck, nice to meet you.
Here is a good cycle layout:
– Week 1 to 12: Testosterone enanthate @ 250 mg every days (500mg/week total)
– Week 1 to 12: HCG @ 250 iu every days (500 iu/week total)
– Week 1 to 14: Arimidex @ every other day (From day 2 up until PCT starts)
After your last testosterone injection, you’ll need to wait 14 days to start PCT. This
allows just enough time for the enanthate ester to clear your system so that you can start
therapy. Remember to continue taking your AI during those 2 weeks. You can also
choose to use Aromasin, the recommended dose is 25mg daily.
Post Cycle Therapy should consist of both Tamoxifen (Nolvadex) and Clomiphene
(Clomid). The combination is important as they work in synergy to help you recover.
Running only one of them will hinder your chance of recovery some. Your PCT protocol
for this cycle should look like the following:
Clomid @ 75/50/50/50 & Nolvadex @ 40/20/20/20
Bushido, I read on Meso-rx under steroid profiles that primo has a half life of 5 days. That means that if u took an injection on day one it would be half out of ur system in 5 days, 3/4 out in 10 days, and 100% in 15 days, correct? Not 100% sure on how that works but that is what i read. When I posted this i thought it meant that 100% of the drug would be gone in ten days. So basically in order for that to work you would need to shoot everything on day one I presume, which would only give you about a week of a very high concentration. Would it be ascanine to expect ANY advantage from one week of high dosage, whilst relying on synergy with say more dianabol in the second week? Which if taken in the morning, might alow for an even faster recovery?? I imagine it would not be a great idea to shoot say 1200 mg on day one for example? Am I correct in the half life timing? With a half life of 5 days there would only be time for one shot in a two weeker? It might be a worthwhile experiment no? LOL What do u think? Better off with the anavar?
SPL documents contain both the content of labeling (all text, tables and figures) for a product along with additional machine readable information (including drug listing data elements and clinical data elements). Drug listing data elements include coded information about the product (including product and generic names, ingredients, ingredient strengths, dosage forms, routes of administration, appearance, DEA schedule) and the packaging (package quantity and type). Clinical data elements include coded information about the clinical use of the product (including indications and use, contraindications, drug interactions, warning and precautions and use in special populations).